[{"id":"8c77c515-8fd7-47a1-b2a0-d210db442390","acronym":"","url":"https://clinicaltrials.gov/study/NCT00977574","created_at":"2021-01-18T03:48:50.533Z","updated_at":"2024-07-02T16:35:03.140Z","phase":"Phase 2","brief_title":"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT00977574","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AKT1","pipe":"","alterations":" ","tags":["AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • temsirolimus • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Ixempra (ixabepilone) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • patupilone (EPO 906)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 349","initiation":"Initiation: 09/14/2009","start_date":" 09/14/2009","primary_txt":" Primary completion: 01/31/2015","primary_completion_date":" 01/31/2015","study_txt":" Completion: 03/06/2025","study_completion_date":" 03/06/2025","last_update_posted":"2024-05-17"},{"id":"90768b89-c427-470b-b45e-d036704acad6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03093155","created_at":"2024-05-05T01:48:26.040Z","updated_at":"2024-07-02T16:35:03.705Z","phase":"Phase 2","brief_title":"Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab","source_id_and_acronym":"NCT03093155","lead_sponsor":"Yale University","biomarkers":" TUBB3","pipe":"","alterations":" ","tags":["TUBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Ixempra (ixabepilone)"],"overall_status":"Completed","enrollment":" Enrollment 78","initiation":"Initiation: 04/03/2017","start_date":" 04/03/2017","primary_txt":" Primary completion: 12/29/2022","primary_completion_date":" 12/29/2022","study_txt":" Completion: 12/29/2022","study_completion_date":" 12/29/2022","last_update_posted":"2024-05-14"},{"id":"7e855fb6-2cfa-4b75-acc1-f6614ca4a80d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00877500","created_at":"2021-01-18T03:21:15.288Z","updated_at":"2024-07-02T16:35:08.042Z","phase":"Phase 2","brief_title":"Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy","source_id_and_acronym":"NCT00877500","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ixempra (ixabepilone) • patupilone (EPO 906)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 03/30/2009","start_date":" 03/30/2009","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-23"},{"id":"fa0a16d9-bc9f-4cf1-a454-6909e3b1d1b2","acronym":"TavIx","url":"https://clinicaltrials.gov/study/NCT00630032","created_at":"2021-01-18T02:20:34.220Z","updated_at":"2024-07-02T16:35:18.454Z","phase":"Phase 3","brief_title":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","source_id_and_acronym":"NCT00630032 - TavIx","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • HR negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HR negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • 5-fluorouracil • cyclophosphamide • epirubicin • Ixempra (ixabepilone)"],"overall_status":"Completed","enrollment":" Enrollment 762","initiation":"Initiation: 09/01/2007","start_date":" 09/01/2007","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 09/03/2020","study_completion_date":" 09/03/2020","last_update_posted":"2024-02-21"},{"id":"d706a100-20c3-4942-98f1-dac486c56909","acronym":"ORIENTA","url":"https://clinicaltrials.gov/study/NCT06102824","created_at":"2023-10-26T15:14:20.313Z","updated_at":"2024-07-02T16:35:23.595Z","phase":"Phase 2","brief_title":"Organoid-based Functional Precision Therapy for Advanced Breast Cancer","source_id_and_acronym":"NCT06102824 - ORIENTA","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • ER positive + PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • ER positive + PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • Ixempra (ixabepilone) • Lipusu (liposomal paclitaxel) • utidelone IV (UTD1)"],"overall_status":"Recruiting","enrollment":" Enrollment 252","initiation":"Initiation: 01/20/2024","start_date":" 01/20/2024","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-01-12"},{"id":"c888c59b-5866-45b5-b5e1-8236364f4e96","acronym":"ATTAIN","url":"https://clinicaltrials.gov/study/NCT02915744","created_at":"2021-01-18T14:18:52.943Z","updated_at":"2024-07-02T16:35:50.577Z","phase":"Phase 3","brief_title":"A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine","source_id_and_acronym":"NCT02915744 - ATTAIN","lead_sponsor":"Nektar Therapeutics","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • capecitabine • albumin-bound paclitaxel • irinotecan • Halaven (eribulin mesylate) • vinorelbine tartrate • Ixempra (ixabepilone) • Onzeald (etirinotecan pegol)"],"overall_status":"Completed","enrollment":" Enrollment 178","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2023-04-14"},{"id":"505b5664-6299-4f2b-8f09-9777d54d0bb1","acronym":"PREDATOR","url":"https://clinicaltrials.gov/study/NCT02067416","created_at":"2021-01-18T09:31:21.126Z","updated_at":"2024-07-02T16:35:56.554Z","phase":"Phase 2","brief_title":"PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer","source_id_and_acronym":"NCT02067416 - PREDATOR","lead_sponsor":"Jenny C. Chang, MD","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • albumin-bound paclitaxel • epirubicin • Ixempra (ixabepilone)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 06/01/2014","primary_completion_date":" 06/01/2014","study_txt":" Completion: 06/01/2014","study_completion_date":" 06/01/2014","last_update_posted":"2023-02-02"},{"id":"73ded696-b188-40bd-9d00-ba4f1710bd92","acronym":"CALGB 40502","url":"https://clinicaltrials.gov/study/NCT00785291","created_at":"2021-01-18T02:58:05.514Z","updated_at":"2024-07-02T16:36:02.771Z","phase":"Phase 3","brief_title":"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer","source_id_and_acronym":"NCT00785291 - CALGB 40502","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • albumin-bound paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Ixempra (ixabepilone) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • patupilone (EPO 906)"],"overall_status":"Completed","enrollment":" Enrollment 799","initiation":"Initiation: 10/13/2008","start_date":" 10/13/2008","primary_txt":" Primary completion: 12/31/2013","primary_completion_date":" 12/31/2013","study_txt":" Completion: 06/15/2017","study_completion_date":" 06/15/2017","last_update_posted":"2022-10-10"},{"id":"66c55ef9-ef6b-4a6d-a743-799331b5649a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00866905","created_at":"2021-01-18T03:18:27.162Z","updated_at":"2025-02-25T14:30:51.737Z","phase":"Phase 2","brief_title":"Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer","source_id_and_acronym":"NCT00866905","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Ixempra (ixabepilone) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 168","initiation":"Initiation: 04/01/2009","start_date":" 04/01/2009","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2021-11-22"},{"id":"ba7b0b88-3ab3-421d-9de0-1c64d1ab0853","acronym":"","url":"https://clinicaltrials.gov/study/NCT00207090","created_at":"2021-01-18T00:42:15.519Z","updated_at":"2024-07-02T16:36:39.328Z","phase":"Phase 1","brief_title":"Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer","source_id_and_acronym":"NCT00207090","lead_sponsor":"R-Pharm","biomarkers":" CYP3A4","pipe":"","alterations":" ","tags":["CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ixempra (ixabepilone) • rifampicin"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 09/01/2005","start_date":" 09/01/2005","primary_txt":" Primary completion: 11/01/2008","primary_completion_date":" 11/01/2008","study_txt":" Completion: 11/01/2008","study_completion_date":" 11/01/2008","last_update_posted":"2020-11-02"},{"id":"f2619e7c-4c3a-4c4e-a999-ce89a186e179","acronym":"","url":"https://clinicaltrials.gov/study/NCT01818999","created_at":"2021-01-18T08:05:03.929Z","updated_at":"2024-07-02T16:36:41.804Z","phase":"Phase 2","brief_title":"Ixabepilone and SBRT For Metastatic Breast Cancer","source_id_and_acronym":"NCT01818999","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ixempra (ixabepilone)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2013","start_date":" 08/01/2013","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2020-08-20"},{"id":"6e07b65b-42ca-46be-9269-31596eebf4c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01084057","created_at":"2021-01-18T04:16:30.319Z","updated_at":"2024-07-02T16:36:53.936Z","phase":"Phase 1","brief_title":"Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT01084057","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zolinza (vorinostat) • Ixempra (ixabepilone) • patupilone (EPO 906)"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 05/17/2010","start_date":" 05/17/2010","primary_txt":" Primary completion: 11/12/2012","primary_completion_date":" 11/12/2012","study_txt":" Completion: 09/27/2019","study_completion_date":" 09/27/2019","last_update_posted":"2019-11-05"},{"id":"ea2bb81e-0ec6-4ade-9cd8-bb36975d63db","acronym":"","url":"https://clinicaltrials.gov/study/NCT00005807","created_at":"2021-01-17T23:51:21.455Z","updated_at":"2024-07-02T16:37:06.355Z","phase":"Phase 1","brief_title":"Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer","source_id_and_acronym":"NCT00005807","lead_sponsor":"Albert Einstein College of Medicine","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ixempra (ixabepilone) • patupilone (EPO 906)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 07/01/2000","start_date":" 07/01/2000","primary_txt":" Primary completion: 08/01/2004","primary_completion_date":" 08/01/2004","study_txt":" Completion: 08/01/2004","study_completion_date":" 08/01/2004","last_update_posted":"2018-10-09"},{"id":"4369463c-f674-4a12-a285-1a85fafb9d85","acronym":"","url":"https://clinicaltrials.gov/study/NCT00923130","created_at":"2021-01-18T03:34:23.691Z","updated_at":"2024-07-02T16:37:11.453Z","phase":"Phase 2","brief_title":"Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer","source_id_and_acronym":"NCT00923130","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Ixempra (ixabepilone)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/07/2009","start_date":" 01/07/2009","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2018-04-17"},{"id":"a678500a-79fa-4715-8365-d79669ff7307","acronym":"TITAN","url":"https://clinicaltrials.gov/study/NCT00789581","created_at":"2021-01-18T02:59:38.958Z","updated_at":"2025-02-25T14:30:24.886Z","phase":"Phase 3","brief_title":"A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer","source_id_and_acronym":"NCT00789581 - TITAN","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Ixempra (ixabepilone) • cyclophosphamide intravenous • patupilone (EPO 906)"],"overall_status":"Completed","enrollment":" Enrollment 614","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 11/01/2016","study_completion_date":" 11/01/2016","last_update_posted":"2017-07-02"},{"id":"2f420ad7-706c-4420-afa4-06938b80cf83","acronym":"","url":"https://clinicaltrials.gov/study/NCT01075100","created_at":"2021-01-18T04:14:09.306Z","updated_at":"2025-02-25T14:31:43.629Z","phase":"Phase 2","brief_title":"Ixabepilone + Carboplatin Metastatic Breast Cancer","source_id_and_acronym":"NCT01075100","lead_sponsor":"US Oncology Research","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Ixempra (ixabepilone) • patupilone (EPO 906)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 01/01/2010","start_date":" 01/01/2010","primary_txt":" Primary completion: 06/01/2013","primary_completion_date":" 06/01/2013","study_txt":" Completion: 06/01/2013","study_completion_date":" 06/01/2013","last_update_posted":"2016-12-07"},{"id":"aaa379a5-f521-49bd-b248-eb6f907e780f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01349088","created_at":"2021-01-18T05:30:36.786Z","updated_at":"2024-07-02T16:37:28.328Z","phase":"Phase 1/2","brief_title":"Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer","source_id_and_acronym":"NCT01349088","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" HER-2 • PGR • KIT","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • PGR • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Ixempra (ixabepilone) • motesanib (AMG 706) • patupilone (EPO 906)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":" Completion: 09/01/2018","study_completion_date":" 09/01/2018","last_update_posted":"2016-10-21"}]